Functional Improvement Seen With C1q Inhibitor in Guillain-Barré Syndrome

ANX005 is a C1q inhibitor that is administered intravenously and works by blocking the activation of classical complement pathway.

Related Keywords

Bangladesh ,Philippines , ,International Guillain Barr ,Drug Administration ,Research Council ,Peripheral Nerve Society Annual Meeting On ,Medical Research Council ,Douglas Love ,Western International Guillain Barr ,Syndrome Outcomes Study ,Biologics License Application ,Nerve Society Annual Meeting ,Fast Track ,Orphan Drug ,